Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): Results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study

Authors :: Y Terada
Brian G. Weinshenker
Yuichi Kawata
Jeffrey Bennett
Svitlana Shkrobot
Gaelle Klingelschmitt
Benjamin Greenberg
Athos Gianella-Borradori
Anthony Traboulsee
Padraig Wright
H.C. von Büdingen
Takashi Yamamura
Edward Fox
Lech Szczechowski
Source :: Journal of the Neurological Sciences. 405:171
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Pediatrics
medicine.medical_specialty
Neuromyelitis optica
business.industry
medicine.disease
Relapse prevention
Placebo
Clinical study
Double blind
Neurology
medicine
Spectrum disorder
Neurology (clinical)
business

Full Text Access

Tools